Wellington Management Group’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$140M Buy
3,671,887
+722,153
+24% +$30.4M 0.02% 454
2026
Q2
$139M Buy
2,949,734
+1,644,985
+126% +$40.6M 0.02% 469
2026
Q1
$24.7M Buy
1,304,749
+84,082
+7% +$1.43M ﹤0.01% 929
2025
Q4
$16.3M Buy
1,220,667
+964,301
+376% +$11.9M ﹤0.01% 1112
2025
Q3
$3.02M Sell
256,366
-5,587
-2% -$52.1K ﹤0.01% 1549
2025
Q2
$1.7M Buy
261,953
+36,025
+16% +$237K ﹤0.01% 1610
2025
Q1
$1.32M Buy
225,928
+31,437
+16% +$225K ﹤0.01% 1647
2024
Q4
$1.35M Buy
194,491
+8,769
+5% +$60.3K ﹤0.01% 1658
2024
Q3
$1.06M Buy
185,722
+109,152
+143% +$759K ﹤0.01% 1700
2024
Q2
$552K Buy
76,570
+21,505
+39% +$188K ﹤0.01% 1771
2024
Q1
$518K Buy
+55,065
New +$314K ﹤0.01% 1806

Other funds holding DFTX

Wellington Management Group's DFTX Position: Q3 2026 in Review

Wellington Management Group increased its Definium Therapeutics (DFTX) stake by 24% in Q3 2026, buying an estimated $30.4M and bringing the position to 3,671,887 shares worth $140M. The position accounts for 0.02% of the portfolio, ranked #454.

Wellington Management Group first reported a position in DFTX in Q1 2024 and has held it in 11 quarters since. 270 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Wellington Management Group held 3,671,887 shares of Definium Therapeutics worth $140M as of Q3 2026.
  • Wellington Management Group bought 722,153 Definium Therapeutics shares in Q3 2026, an estimated $30.4M.
  • Definium Therapeutics made up 0.02% of Wellington Management Group's portfolio in Q3 2026, its #454 holding.
  • Wellington Management Group first reported a position in Definium Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • 270 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Wellington Management Group's 13F filing for Q3 2026, filed 16 Nov 2026.